158 related articles for article (PubMed ID: 22795090)
1. Metronomic therapy for gynecologic cancers.
Su WH; Ho TY; Li YT; Lu CH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2012 Jun; 51(2):167-78. PubMed ID: 22795090
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy.
Mutsaers AJ
Top Companion Anim Med; 2009 Aug; 24(3):137-43. PubMed ID: 19732732
[TBL] [Abstract][Full Text] [Related]
3. Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
Aigner J; Bischofs E; Hallscheidt P; Sohn C; Schneeweiss A; Eichbaum M
Anticancer Drugs; 2011 Nov; 22(10):1030-3. PubMed ID: 21970854
[TBL] [Abstract][Full Text] [Related]
4. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
[TBL] [Abstract][Full Text] [Related]
5. The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field.
Gaspar TB; Henriques J; Marconato L; Queiroga FL
Vet Comp Oncol; 2018 Mar; 16(1):2-11. PubMed ID: 28317239
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.
Sarafraz-Yazdi E; Gorelick C; Wagreich AR; Salame G; Angert M; Gartman CH; Gupta V; Bowne WB; Lee YC; Abulafia O; Pincus MR; Michl J
Ann Clin Lab Sci; 2015; 45(6):650-8. PubMed ID: 26663795
[TBL] [Abstract][Full Text] [Related]
8. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
9. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer.
Gille J; Spieth K; Kaufmann R
J Dtsch Dermatol Ges; 2005 Jan; 3(1):26-32. PubMed ID: 16353746
[TBL] [Abstract][Full Text] [Related]
10. [Guidelines for proper use of antineoplastic agents. Gynecologic cancer].
Ochiai K; Okamoto A; Katsumata N
Gan To Kagaku Ryoho; 2002 Jun; 29(6):1047-54. PubMed ID: 12109445
[No Abstract] [Full Text] [Related]
11. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
12. [Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer].
Zhang S; Liu J; Cheng Y
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):232-9. PubMed ID: 25936888
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
[TBL] [Abstract][Full Text] [Related]
14. Dose-dense approaches to ovarian cancer treatment.
Katsumata N
Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
[TBL] [Abstract][Full Text] [Related]
15. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Wang Z; Fu S
Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
[TBL] [Abstract][Full Text] [Related]
16. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
17. Metronomic therapy for breast cancer.
Kaur H; Budd GT
Curr Oncol Rep; 2004 Jan; 6(1):49-52. PubMed ID: 14664761
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
19. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.
Lambrescu I; Fica S; Martins D; Spada F; Cella C; Bertani E; Rubino M; Gibelli B; Grana C; Bonomo G; Funicelli L; Ravizza D; Pisa E; Zerini D; Ungaro A; Fazio N;
Cancer Treat Rev; 2017 Apr; 55():46-56. PubMed ID: 28314176
[TBL] [Abstract][Full Text] [Related]
20. Metronomic chemotherapy and nanocarrier platforms.
Abu Lila AS; Ishida T
Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]